Calidi Biotherapeutics (CLDI) Competitors $0.41 -0.04 (-9.15%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.04 (+9.58%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLDI vs. VNRX, PEPG, ATNM, STTK, ICCC, VRCA, OKYO, ONCY, CUE, and MURAShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include VolitionRx (VNRX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), Shattuck Labs (STTK), ImmuCell (ICCC), Verrica Pharmaceuticals (VRCA), OKYO Pharma (OKYO), Oncolytics Biotech (ONCY), Cue Biopharma (CUE), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. VolitionRx PepGen Actinium Pharmaceuticals Shattuck Labs ImmuCell Verrica Pharmaceuticals OKYO Pharma Oncolytics Biotech Cue Biopharma Mural Oncology Calidi Biotherapeutics (NYSE:CLDI) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends. Which has stronger earnings & valuation, CLDI or VNRX? Calidi Biotherapeutics has higher earnings, but lower revenue than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K230.70-$29.22MN/AN/AVolitionRx$1.31M39.40-$35.32M-$0.27-1.89 Does the media refer more to CLDI or VNRX? In the previous week, VolitionRx had 6 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 9 mentions for VolitionRx and 3 mentions for Calidi Biotherapeutics. VolitionRx's average media sentiment score of 0.69 beat Calidi Biotherapeutics' score of 0.23 indicating that VolitionRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Calidi Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VolitionRx 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CLDI or VNRX? Calidi Biotherapeutics currently has a consensus target price of $10.00, indicating a potential upside of 2,367.92%. VolitionRx has a consensus target price of $3.75, indicating a potential upside of 633.14%. Given Calidi Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Calidi Biotherapeutics is more favorable than VolitionRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor CLDI or VNRX? VolitionRx received 14 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/AVolitionRxOutperform Votes1419.72%Underperform Votes5780.28% Is CLDI or VNRX more profitable? Calidi Biotherapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% VolitionRx -2,321.14%N/A -163.39% Which has more volatility & risk, CLDI or VNRX? Calidi Biotherapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Do institutionals & insiders hold more shares of CLDI or VNRX? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 10.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryCalidi Biotherapeutics beats VolitionRx on 8 of the 14 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$11.54M$2.93B$5.37B$19.41BDividend YieldN/A1.72%5.22%3.83%P/E RatioN/A30.5026.8434.23Price / Sales230.70400.15392.3434.85Price / CashN/A168.6838.2517.51Price / Book-0.173.286.794.69Net Income-$29.22M-$72.17M$3.23B$1.02B7 Day Performance1.30%4.28%4.07%-1.34%1 Month Performance-7.91%7.62%12.52%9.79%1 Year PerformanceN/A-28.15%16.83%3.27% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics1.9253 of 5 stars$0.41-9.1%$10.00+2,367.9%N/A$11.54M$50,000.000.0038Gap UpVNRXVolitionRx1.889 of 5 stars$0.49-1.0%$3.33+573.7%-33.7%$49.86M$1.23M-1.3780News CoverageGap UpPEPGPepGen3.1465 of 5 stars$1.51+0.7%$9.67+540.2%-88.3%$49.41MN/A-0.5130Gap UpATNMActinium Pharmaceuticals1.2012 of 5 stars$1.55+4.7%$4.00+158.1%N/A$48.35M$81,000.00-1.1230Trending NewsSTTKShattuck Labs2.5735 of 5 stars$0.99+4.4%$7.50+657.6%-86.2%$47.42M$4.61M-0.65100ICCCImmuCell0.1721 of 5 stars$5.24+3.4%N/A+16.9%$47.13M$26.49M-10.4870Earnings ReportVRCAVerrica Pharmaceuticals4.2265 of 5 stars$0.51+15.1%$9.50+1,776.4%-92.6%$46.81M$7.57M-0.2840Analyst RevisionOKYOOKYO Pharma1.7164 of 5 stars$1.38-4.8%$7.00+407.2%+24.2%$46.69MN/A0.007ONCYOncolytics Biotech1.7174 of 5 stars$0.54+4.0%$4.33+702.5%-61.6%$46.67MN/A-2.0030Earnings ReportAnalyst ForecastGap DownCUECue Biopharma3.8841 of 5 stars$0.75-3.7%$3.00+299.5%-64.2%$46.43M$9.29M-0.8360MURAMural Oncology2.322 of 5 stars$2.64+0.4%$13.00+392.4%-21.0%$45.59MN/A-0.29119Earnings Report Related Companies and Tools Related Companies VolitionRx Competitors PepGen Competitors Actinium Pharmaceuticals Competitors Shattuck Labs Competitors ImmuCell Competitors Verrica Pharmaceuticals Competitors OKYO Pharma Competitors Oncolytics Biotech Competitors Cue Biopharma Competitors Mural Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDI Stock Free CLDI Stock Alerts